cGAS-STING signaling in Alzheimer's disease: Microglial mechanisms and therapeutic opportunities

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Alzheimer's disease (AD) is increasingly viewed as a neuroinflammatory disorder linked to microglial dysfunction.
• The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway is critically involved in neuroinflammation and AD pathology.
• Chronic cGAS-STING activation exacerbates neurodegeneration through sustained type I interferon release and pro-inflammatory cytokine production.

Purpose of the Study:

• To review the role of the cGAS-STING pathway in Alzheimer's disease.
• To explore the therapeutic potential of targeting the cGAS-STING pathway in AD using small-molecule inhibitors.
• To discuss the challenges and future directions for cGAS-STING inhibitor development in AD treatment.

Main Methods:

• Review of preclinical studies on cGAS-STING pathway involvement in AD.
• Analysis of pharmacological inhibitors targeting cGAS-STING.
• Discussion of challenges related to therapeutic targeting, including blood-brain barrier penetration and immune specificity.

Main Results:

• Preclinical studies indicate that cGAS-STING inhibitors can mitigate amyloid beta and tau pathology.
• Inhibitors have shown potential in reducing microglial reactivity and improving cognitive outcomes in AD models.
• The pathway's essential physiological roles present challenges for targeted inhibition without disrupting neuroimmune homeostasis.

Conclusions:

• The cGAS-STING pathway is a significant contributor to AD neuroinflammation and neurodegeneration.
• Small-molecule inhibitors targeting cGAS-STING represent a promising therapeutic strategy for AD.
• Overcoming challenges like BBB penetration, immune specificity, and safety is crucial for clinical translation of cGAS-STING inhibitors in AD.